Results 11 to 20 of about 746,792 (308)
Renal tumor biomarkers (Review)
Experimental and Therapeutic Medicine, 2021 One of the most common types of cancer worldwide (9th most commonly diagnosed) is renal cell carcinoma (RCC). It is more common in developed countries and it usually develops in individuals between 60 and 70 years of age. The earlier the disease is identified, the lower the morbidity.
Ovidiu, Bratu +11 more
openaire +3 more sources
The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension [PDF]
, 2015 We assessed the predictive ability of selected biomarkers using N-terminal pro-brain natriuretic peptide (NT-proBNP) as the benchmark and tried to establish a multi-biomarker approach to heart failure (HF) in hypertensive patients. In 120 hypertensive
Agata Bielecka-Dabrowa +10 more
core +7 more sources
Biomarkers of Pediatric Brain Tumors [PDF]
Frontiers in Pediatrics, 2013 Background and Need for Novel Biomarkers: Brain tumors are the leading cause of death by solid tumors in children. Although improvements have been made in their radiological detection and treatment, our capacity to promptly diagnose pediatric brain tumors in their early stages remains limited. This contrasts several other cancers where serum biomarkers
Mark D Russell +3 more
openaire +4 more sources
The importance of circulating tumor products as „liquid biopsies” in colorectal cancer [PDF]
, 2018 Liquid biopsies represent an array of plasma analysis tests that are studied to evaluate and identify circulating tumor products, especially circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA).
Calborean, Veronica +6 more
core +4 more sources
Cancer Control, 2009 Background Morphologic and histopathologic markers have been the backbone for the classification and prognostic assessment of melanoma. Availability of an increasing number of molecular markers, however, provides the potential for refining diagnostic and prognostic categories in this disease.
Selma, Ugurel +2 more
openaire +2 more sources
Serum biomarkers and clinical characteristics of patients with Hodgkin lymphoma [PDF]
Vojnosanitetski Pregled, 2018 Background/Aim. In classical Hodgkin’s lymphoma (cHL) the existing prognostic scoring systems do not include markers that adequately reflect the interaction of malignant Hodgkin and Reed-Sternberg (HRS) cells and tumor environment.
Simonović Olivera +6 more
doaj +1 more source
Ubiquinol Reduces Muscle Wasting but Not Fatigue in Tumor-Bearing Mice [PDF]
, 2014 Purpose: Fatigue is the most common and distressing symptom reported by cancer patients during and after treatment. Tumor growth increases oxidative stress and cytokine production, which causes skeletal muscle wasting and cardiac dysfunction. The purpose
Clark, Yvonne +3 more
core +2 more sources
Translational progress on tumor biomarkers [PDF]
Thoracic Cancer, 2015 AbstractThere is an urgent need to apply basic research achievements to the clinic. In particular, mechanistic studies should be developed by bench researchers, depending upon clinical demands, in order to improve the survival and quality of life of cancer patients.
Guo, Hongwei +8 more
openaire +3 more sources
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib [PDF]
, 2016 ARQ 197-215 was a randomized placebo-controlled phase II study testing the MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It identified tumor MET as a key biomarker in HCC.
Abbadessa, Giovanni +19 more
core +4 more sources
Hopes on immunotherapy targeting B7-H3 in neuroblastoma
Translational Oncology, 2023 Neuroblastoma is one of the most aggressive cancer forms in children, with highly heterogenous clinical manifestations ranging from spontaneous regression to high metastatic capacity.
Rafael Pulido, Caroline E. Nunes-Xavier
doaj +1 more source